top of page

Mon, January 9th 2023

ProtonDx and Katalyst Announce Strategic Partnership to Distribute Dragonfly In Vitro Diagnostic

Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly System able to detect five common respiratory pathogens at once.

Screen Shot 2023-07-21 at 2.04.42 PM.png

London, UK – 09 January 2023: ProtonDx, an in vitro diagnostic company designing, manufacturing and marketing rapid, accurate, multi‑pathogen, point‑of‑need diagnostic solutions, announced a strategic partnership with innovative commercial POCT provider Katalyst Laboratories, to distribute ProtonDx’s DragonflyTM rapid in vitro diagnostic system.

Under the terms of the agreement, ProtonDx has granted Katalyst exclusive rights to the distribution of Dragonfly multi‑pathogen detection system in a variety of Katalyst client segments. Katalyst has focused on providing disruptive diagnostic solutions that deliver customer‑centric services to meet the needs of the rapidly evolving diagnostics landscape, making them an ideal partner for the new Dragonfly system.

Bob Enck, Chairman and President of ProtonDx, stated: 

 

“I am pleased to announce our strategic partnership with Katalyst for the distribution of our proven Dragonfly diagnostic system. Katalyst are leading the evolution of in‑field diagnostic testing for the film and TV production industries, providing ready access to novel diagnostic solutions to support operational continuity for these people‑centric businesses. Dragonfly is a potential game‑changer in the diagnostics industry ‑ providing rapid and accurate results, irrespective of location.”

Bob Enck, Chairman and President of ProtonDx, stated: 

“Dragonfly is a potential game‑changer in the diagnostics industry ‑ providing quick, cost‑effective, and confident results, irrespective of location. With its demonstrated value at major international sporting events, the interest in Dragonfly throughout the sporting world and other key industries is rapidly expanding across Europe.”

In February 2023 ProtonDx announced that it had received a CTDA approval for Dragonfly. The test is now available in all European Union countries and United Kingdom. The robust, accurate system is poised to help revolutionise rapid infectious disease diagnosis and tracking worldwide.

bottom of page